Tag «PHASE 2»

Rovafovir Etalafenamide

It’s only fair to share… Rovafovir etalafenamide GS-9131 UNII-U8S0IC8DY7  ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate L-Alanine, N-((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydro-2-furanyl)oxy)methyl)phenoxyphosphinyl)-, ethyl ester CAS: 912809-27-9 Chemical Formula: C21H24FN6O6P Molecular Weight: 506.43 Originator Gilead Sciences Class Antiretrovirals; Purine nucleosides; Small molecules Mechanism of Action Nucleoside reverse transcriptase inhibitors Phase II HIV-1 infections 03 Apr 2018 Phase-II clinical trials in HIV-1 infections (Treatment-experienced) in Uganda (PO) (NCT03472326) 21 Mar 2018 Gilead …

Beclabuvir

It’s only fair to share… BMS-791325, Beclabuvir IN PHASE 2 for Hepatitis C (HCV) An NS5B inhibitor. BMS-791325 preferably is CAS 958002-33-0 958002-36-3 (as hydrochloride) C36 H45 N5 O5 S, 659.838 Cycloprop(d)indolo(2,1-a)(2)benzazepine-9-carboxamide, 12-cyclohexyl-N-((dimethylamino)sulfonyl)-4b,5,5a,6-tetrahydro-3-methoxy-5a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)-, (4bS,5aR)- (4bS,5aR)-12-Cyclohexyl-N-(dimethylsulfamoyl)-3-methoxy-5a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)-4b,5,5a,6-tetrahydrocyclopropa(d)indolo(2,1-a)(2)benzazepine-9-carboxamide (4bS,5aR)-12-Cyclohexyl-N-(dimethylsulfamoyl)-3-methoxy-5a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)-4b,5,5a,6-tetrahydrocyclopropa(d)indolo(2,1-a)(2)benzazepine-9-carboxamide (1aR,12bS)-8-Cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-[(3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl]-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide Cycloprop [d] indolo [2, 1 -a] [2]benzazepine-5-carboxamide, 8-cyclohexyl-N- [(dimethylamino)sulfonyl]-l,la,2,12b-tetrahydro-ll-methoxy-la-[(3-methyl-3,8- diazabicyclo[3.2.1]oct-8-yl)carbonyl]-, (laR,12bS)- Bristol-Myers Squibb (Originator) RNA-Directed RNA Polymerase (NS5B) …

Golvatinib, ゴルバチニブ

It’s only fair to share… Golvatinib E-7050, cas 928037-13-2 1-N’-[2-fluoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1,1-Cyclopropanedicarboxamide, N-[2-fluoro-4-[[2-[[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]amino]-4-pyridinyl]oxy]phenyl]-N’-(4-fluorophenyl)- [ACD/Index Name] 516Z3YP58E 928037-13-2 [RN] 9565 E7050, ゴルバチニブ Molecular Formula: C33H37F2N7O4 Molecular Weight: 633.701 g/mol N’-[2-fluoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide UNII:516Z3YP58E Originator Eisai Co Ltd Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Piperazines; Piperidines; Pyridines; Small molecules Mechanism of Action Angiogenesis inhibitors; Proto oncogene protein c met inhibitors; Vascular endothelial growth factor receptor-2 antagonists Discontinued Gastric cancer; …

Epitinib

It’s only fair to share… Epitinib succinate; HMPL-813; Huposuan yipitini 1203902-67-3, 430.50, C24 H26 N6 O2 1-Piperazinecarboxamide, 4-ethyl-N-[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]- 4-Ethyl-N-[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]-1-piperazinecarboxamide Cancer; Glioblastoma; Non-small-cell lung cancer Epitinib is in phase I clinical trials by Hutchison MediPharma for the treatment of solid tumours. Epitinib succinate is an oral EGFR tyrosine kinase inhibitor in early clinical development at Hutchison China MediTech (Chi-Med) for the …

AKN 028

It’s only fair to share… AKN-028 CAS 1175017-90-9 Chemical Formula: C17H14N6 Molecular Weight: 302.33 N-3-(1H-indol-5-yl)-5-pyridin-4-yl-pyrazine-2,3-diamine N2-(1H-indol-5-yl)-6-(pyridin-4-yl)pyrazine-2,3-diamine Originator Swedish Orphan Biovitrum Developer Akinion Pharmaceuticals Class Antineoplastics; Small molecules Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c-kit inhibitors Phase I/II Acute myeloid leukaemia 01 Mar 2016 Akinion Pharmaceuticals terminates phase I/II trial in Acute myeloid leukaemia in Czech Republic, …

GSK2248761A , IDX899, Fosdevirine

It’s only fair to share… GSK2248761A , IDX899, Fosdevirine, Fosdevirine; IDX899; IDX-899; GSK2248761; cas 1018450-26-4; GSK-2248761, IDX 12899 1018450-26-4 CAS R FORM ROTATION (-) Molecular Formula: C20H17ClN3O3P Molecular Weight: 413.798 g/mol  Phosphinic acid, P-[2-(aminocarbonyl)-5-chloro-1H-indol-3-yl]-P-[3-[(1E)-2-cyanoethenyl]-5-methylphenyl]-, methyl ester, [P(R)]- Methyl (R)-(2-carbamoyl-5-chloro-1H-indol-3-yl){3-[(E)-2-cyanovinyl]-5-methylphenyl}phosphinate Phosphinic acid, P-[2-(aminocarbonyl)-5-chloro-1H-indol-3-yl]-P-[3-[(E)-2-cyanoethenyl]-5-methylphenyl]-, methyl ester, (R)- 5DV Methyl (R)-(2-carbamoyl-5-chloro-1H-indol-3-yl)[3-(2-cyanoethyl)-5-methylphenyl]phosphinate [R(P)]-(2-Carbamoyl-5-chloro-1H-indol-3-yl)[3-(2-cyanovinyl)-5-methylphenyl]phosphinic acid methyl ester Phase II clinical trials …

OLINCIGUAT

It’s only fair to share… OLINCIGUAT cas 1628732-62-6 Chemical Formula: C21H16F5N7O3 UNII-PD5F4ZXD21 Molecular Weight: 509.4 Olinciguat is a guanylate cyclase activator drug candidate. (2R)-3,3,3-trifluoro-2-{[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]- 5-(1,2-oxazol-3-yl)-1H-pyrazol- 3-yl}pyrimidin-4-yl)amino]methyl}-2-hydroxypropanamide Originator Ironwood Pharmaceuticals Class Antifibrotics; Cardiovascular therapies Mechanism of Action Soluble guanylyl cyclase agonists Orphan Drug StatusNo New Molecular EntityYes Highest Development Phases Phase II Gastrointestinal disorders; Sickle cell anaemia Phase I Cardiovascular disorders; …

TRILACICLIB, G1T28

It’s only fair to share… Trilaciclib Molecular FormulaC24H30N8O Average mass446.548 Da G1T 28 CAS 1374743-00-6 2′-{[5-(4-Methyl-1-piperazinyl)-2-pyridinyl]amino}-7′,8′-dihydro-6’H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one G1T28, SHR 6390 Spiro[cyclohexane-1,9′(6’H)-pyrazino[1‘,2’:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, 7′,8′-dihydro-2‘-[[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino]- 7′,8′-Dihydro-2′-[[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino]spiro[cyclohexane-1,9′(6’H)-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one 2′-[[5-(4-Methylpiperazin-1-yl)pyridin-2-yl]amino}-7′,8′-dihydro-6’H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one UNII:U6072DO9XG Reduction of Chemotherapy-Induced Myelosuppression Trilaciclib dihydrochloride 1977495-97-8 In phase II clinical development as a chemoprotectant at G1 Therapeutics for first- or second-line treatment in patients with metastatic triple negative breast cancer, in …

BMS-986020

It’s only fair to share… BMS-986020 AM-152; BMS-986020; BMS-986202 cas 1257213-50-5 Chemical Formula: C29H26N2O5 Molecular Weight: 482.536 (R)-1-(4′-(3-methyl-4-(((1-phenylethoxy)carbonyl)amino)isoxazol-5-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid Cyclopropanecarboxylic acid, 1-(4′-(3-methyl-4-((((1R)-1-phenylethoxy)carbonyl)amino)-5-isoxazolyl)(1,1′-biphenyl)-4-yl)- 1-(4′-(3-Methyl-4-(((((R)-1-phenylethyl)oxy)carbonyl)amino)isoxazol-5-yl)biphenyl-4-yl)cyclopropanecarboxylic acid UNII: 38CTP01B4L For treatment for pulmonary fibrosis, phase 2, The lysophosphatidic acid receptor, LPA1, has been implicated as a therapeutic target for fibrotic disorders Lysophospholipids (LPs), including lysophosphatidic acid (LPA), sphingosine 1-phospate (S1P), …

Funapide, TV 45070, XEN-402, фунапид فونابيد 呋纳匹特

It’s only fair to share… Funapide TV 45070,  XEN-402,  Funapide, (+)- фунапид فونابيد 呋纳匹特 Molecular FormulaC22H14F3NO5 Average mass429.345 Da (S)-1′-[(5-Methyl-2-furyl)methyl]spiro[6H-furo[3,2-f][1,3]benzodioxole-7,3′-indoline]-2′-one Spiro(furo(2,3-F)-1,3-benzodioxole-7(6H),3′-(3H)indol)-2′(1’H)-one, 1′-((5-(trifluoromethyl)-2-furanyl)methyl)-, (3’S)- (3’S)-1′-((5-(Trifluoromethyl)furan-2-yl)methyl)-2H,6H-spiro(furo(2,3-F)(1,3)benzodioxole-7,3′-indol)-2′(1’H)-one Spiro[furo[2,3-f]-1,3-benzodioxole-7(6H),3′-[3H]indol]-2′(1’H)-one, 1′-[[5-(trifluoromethyl)-2-furanyl]methyl]-, (7S)- TV-45070 UNII-A5595LHJ2L XEN-401-S XEN402 (3’S)-1′-{[5-(trifluoromethyl)furan-2-yl]methyl}-2H-6H-spiro[furo[2,3-f]-1,3-benzodioxole-7,3′-indol]-2′(1’H)-one (7S)-1′-{[5-(Trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3′-indol]-2′(1’H)-one 1259933-16-8 CAS UNII-A5595LHJ2L Phase II clinical trials for Postherpetic neuralgia (PHN) Treatment of Neuropathic Pain Originator Xenon Pharmaceuticals Developer Teva Pharmaceutical Industries; Xenon Pharmaceuticals Class Benzodioxoles; Fluorobenzenes; …